| Drug | Type | Targets |
| ABT-510 | Thrombospondin-1 mimetic peptide | CD36 receptor | AMG 102 | Monoclonal antibody | HGF/SF | Aflibercept | Soluble decoy receptor | VEGF-A,B, PlGF | Bevacizumab | Monoclonal antibody | VEGF-A | Brivanib | Tyrosine kinase inhibitor | FGFR, VEGFR2 | Cediranib | Tyrosine kinase inhibitor | VEGFR1–3, PDGFRβ, c-Kit | Cilengitide | RGD synthetic peptide | Integrins αvβ3, αvβ5 | CT-322 | Fibronectin (adnectin)-based inhibitor | VEGFR1–3 | Dasatinib | Tyrosine kinase inhibitor | PDGFRβ, Src, BCR-ABL, c-Kit, EphA2 | Imatinib | Tyrosine kinase inhibitor | PDGFRβ, BCR-ABL, c-Kit | Lenalidomide | Immunomodulatory and anti-inflammatory | FGF pathway | Pazopanib (GW786034) | Tyrosine kinase inhibitor | VEGFR1–3, PDGFRβ, c-Kit | Sorafenib | Tyrosine kinase inhibitor | VEGFR2,3, BRAF, PDGFRβ, c-Kit, Ras, p38α | Sunitinib | Tyrosine kinase inhibitor | VEGFR2, PDGFRβ, Flt3, c-Kit | Tandutinib (MLN518) | Tyrosine kinase inhibitor | PDGFRβ, Flt3, c-Kit | Vandetanib (ZD6474) | Tyrosine kinase inhibitor | VEGFR2, EGFR, RET | Vatalanib (PTK787) | Tyrosine kinase inhibitor | VEGFR1–3, PDGFRβ, c-Kit | XL-184 | Tyrosine kinase inhibitor | VEGFR2, Met, RET, c-Kit, Flt3, Tie-2 |
|
|